Hoba Therapeutics ApS
CVR 38231170 · Private limited company (ApS) · Active · Very high risk
Hoba Therapeutics ApS is a Private limited company (ApS), founded on , based in Frederiksberg. The company is registered in the industry forskning og eksperimentel udvikling inden for naturvidenskab og teknik. Our model estimates a bankruptcy risk of 11.5% over the next 12 months, which is 8.2 times the average for Danish companies. 10 annual reports have been published, of which 3 more than six months after the end of the financial year. The latest annual report (31 Mar 2026) shows equity of DKK 1.1m and a net result of DKK -67.7m.
Bankruptcy risk for Hoba Therapeutics ApS
8.2 × the average (1.41%) · higher risk than 97% of active Danish companies
Increases the risk
Reduces the risk
The factors show how often companies with the same characteristic went bankrupt compared with the average (“lift”). The risk is a statistical estimate from a model trained on 141,000+ Danish bankruptcies (AUC 0.93) – not a credit rating. Read about the method.
Company details
- CVR number
- 38231170
- Status
- Active
- Company type
- Private limited company (ApS)
- Founded
- (9 years)
- Address
- Nordre Fasanvej 215
2000 Frederiksberg - Municipality
- Frederiksberg
- Industry
- Forskning og eksperimentel udvikling inden for naturvidenskab og teknik (721000)
Bankruptcies in the industry: Anden forskning og eksperimentel udvikling inden for naturvidenskab og teknik - Share capital
- DKK 3.0m
- Employees
- 2 (2018)
- Auditor
- EY Godkendt Revisionspartnerselskab
- Audit opted out
- No
Warning signs
| Annual reports filed late | 3 of 10 |
| Missing annual report | No |
| Negative equity | No |
| Equity ratio | 7.3% |
| Current ratio | 113% |
| Moves (last 2 years) | 1 |
| CEO changes in total | 1 |
| CEO's previous bankruptcies | 0 |
| Other companies at the address | 111 |
| Going-concern uncertainty | Yes |
Financials and key figures
| Financial year | 2026 | 2025 | 2024 |
|---|---|---|---|
| Gross profit | DKK -61.7m | DKK -38.3m | DKK -20.9m |
| Net profit | DKK -67.7m | DKK -43.0m | DKK -27.8m |
| Equity | DKK 1.1m | DKK 26.1m | DKK 69.1m |
| Total assets | DKK 15.6m | DKK 46.1m | DKK 91.5m |
| Cash | DKK 5.7m | DKK 37.1m | – |
| Short-term debt | DKK 13.7m | DKK 9.0m | – |
| Avg. employees | 7 | 8 | – |
Latest annual report: Reporting class B · auditor's statement: Den uafhængige revisors erklæring · EY Godkendt Revisionspartnerselskab.
Filed annual reports
| Reporting period | Published | Days after period end | |
|---|---|---|---|
| 1 Apr 2025 – 31 Mar 2026 | 190 | Late | |
| 1 Apr 2024 – 31 Mar 2025 | 168 | ||
| 1 Apr 2023 – 31 Mar 2024 | 152 | ||
| 1 Apr 2022 – 31 Mar 2023 | 185 | Late | |
| 1 Apr 2021 – 31 Mar 2022 | 197 | Late | |
| 1 Apr 2020 – 31 Mar 2021 | 153 | ||
| 1 Apr 2019 – 31 Mar 2020 | 153 | ||
| 1 Apr 2018 – 31 Mar 2019 | 152 | ||
| 1 Apr 2017 – 31 Mar 2018 | 152 | ||
| 28 Nov 2016 – 31 Mar 2017 | 153 |
The annual report must reach the Danish Business Authority no later than 5 months after the end of the financial year. We mark reports published more than 6 months after as “late”.
Management, owners and auditor
| Role | Name | From | To |
|---|---|---|---|
| CEO | Morten Døssing | ||
| Board | Gunnar Magnus Severus Modée Persson | Current | |
| Board | Gonçalo Nuno Nunes da Silva Rebelo de Andrade | Current | |
| Board | Teit Eliot Johansen | ||
| Board | Lene Gerlach | ||
| Board | Morten Døssing | ||
| Board | Amanda Hayward | ||
| Board | Steen Palle Petersen | ||
| Board | Thor Jespersen | ||
| Board | Camilla Petrycer Hansen | ||
| Board | Lene Gerlach | ||
| Board | Marie Allen Schroeder | ||
| Board | Gonçalo Nuno Nunes da Silva Rebelo de Andrade | ||
| Board | Jean Marcel André Combalbert | ||
| Board | Kuang He | ||
| Owner (33%) | Novo Holdings A/S | Current | |
| Owner (10%) | Danmarks Eksport- og Investeringsfond | Current | |
| Owner (10%) | Eir Ventures I AB | Current | |
| Owner (5%) | MIJ Biotech-Global Limited Partnership | Current | |
| Owner (20%) | EIC Fund | Current | |
| Owner (10%) | Indaco Venture Partners SGR S.p.A. | Current | |
| Owner (5%) | Søren Sylvester Skjærbæk | ||
| Owner (20%) | Teit Eliot Johansen | ||
| Owner (33%) | Novo Holdings A/S | ||
| Owner (10%) | Styrelsen for Forskning og Uddannelse | ||
| Owner (5%) | BOK Holding A/S | ||
| Owner (10%) | Uddannelses- og Forskningsstyrelsen | ||
| Owner (20%) | Teit Eliot Johansen | ||
| Owner (15%) | Teit Eliot Johansen | ||
| Owner (15%) | Uddannelses- og Forskningsstyrelsen | ||
| Owner (5%) | VÆKSTFONDEN | ||
| Owner (5%) | Eir Ventures I AB | ||
| Owner (5%) | Danmarks Eksport- og Investeringsfond | ||
| Owner (15%) | EIC Fund | ||
| Owner (5%) | Indaco Venture Partners SGR S.p.A. | ||
| Auditor | EY Godkendt Revisionspartnerselskab | Current | |
| Auditor | DELOITTE STATSAUTORISERET REVISIONSPARTNERSELSKAB | ||
| Founder | NSGENE A/S | Current |
The CEOs' other companies
Morten Døssing – 10 other companies, of which 1 bankrupt
- STIPE Therapeutics ApS Bankrupt 3 Feb 2026
- ACESION PHARMA ApS Active
- AVILEX PHARMA ApS Active
- Akylox Therapeutics ApS Active
- HyperBio Therapeutics ApS Opløst
- Muna Therapeutics ApS Active
- NMD Pharma A/S Active
- Orbis Medicines ApS Active
- Sulis Therapeutics ApS Active
- de novo foundry ApS Active
Address history (2 moves)
| Nordre Fasanvej 215, 2000 Frederiksberg | |
| c/o COBIS, Ole Maaløes Vej 3, 2200 København N | |
| c/o NsGene A/S, Baltorpvej 154, 2750 Ballerup |
Employees per year
Other companies at the same address
- Nordetect ApS Bankrupt
- ACESION PHARMA ApS Active
- AdaptVac ApS Active
- Adcendo ApS Active
- Akylox Therapeutics ApS Active
- Antraka ApS Opløst
- Augustine Therapeutics Denmark ApS Active
- Autocert ApS Active
- Avancert ApS Active
- B4C ApS Active
- BOOST Pharma ApS Active
- Baekmark IP Consult ApS Active
- Betula Capital ApS Active
- BioPhenyx ApS Active
- Biobridge Partners ApS Active
- Biotinia ApS Active
- CMCAssist ApS Active
- CMCGreenhouse ApS Active
- CMCHoldings ApS Active
- CaMaRa ApS Active
- Catalyst Vaccination A/S Active
- Chris Cording Jønsson Holding ApS Active
- DARERL ApS Active
- DFY ApS Active
- DeltaBot ApS Active
Similar companies in Frederiksberg
- Catalyst Vaccination A/S Frederiksberg
- RefuelBio ApS Frederiksberg
- BioMomentum Advisors ApS Frederiksberg
- Oak Mountain Consulting ApS Frederiksberg
- Biotinia ApS Frederiksberg
- Nordic BioVentures ApS Frederiksberg C
- Zevra Denmark A/S Frederiksberg
- BioPhenyx ApS Frederiksberg
- BioSpringbok ApS Frederiksberg
- Orbis Medicines ApS Frederiksberg
- Epoqe Pharma ApS Frederiksberg
- SJM IP ApS Frederiksberg C
Questions and answers about Hoba Therapeutics ApS
Has Hoba Therapeutics ApS gone bankrupt?
No, Hoba Therapeutics ApS is not registered as bankrupt in the CVR register. Its status is: active.
What is the bankruptcy risk of Hoba Therapeutics ApS?
Our model estimates a bankruptcy risk of 11.5% over the next 12 months (very high risk), which is 8.2 times the average for Danish companies.
Who is the auditor of Hoba Therapeutics ApS?
Hoba Therapeutics ApS most recently used EY Godkendt Revisionspartnerselskab.
When was Hoba Therapeutics ApS founded?
Hoba Therapeutics ApS was founded on 28 November 2016.
What is the equity of Hoba Therapeutics ApS?
Equity was DKK 1.1m according to the annual report for the period ending 31 March 2026.
Source: the CVR register and annual reports published by the Danish Business Authority. The information is updated continuously.